BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cyclosporine (Vevye) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cyclosporine (Vevye)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07553455-5582@assetmemo.bio
DTSTAMP:20261121T010000Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cyclosporine (Vevye): Phase 4 readout est. (NCT07553455)
DESCRIPTION:Cyclosporine (Vevye)\, phase 4\, Dry Eye Disease.\nStudy: Vevye
  + Flarex Combination Therapy for Dry Eye\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cycl
 osporine-vevye#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07553455
URL:https://assetmemo.bio/drug/cyclosporine-vevye#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224529-5582@assetmemo.bio
DTSTAMP:20261121T010000Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Cyclosporine (Vevye): Phase 4 readout est. (NCT07224529)
DESCRIPTION:Cyclosporine (Vevye)\, phase 4.\nStudy: Efficacy of Vevye Ophth
 almic Solution for the Treatment of Meibomian Gland Dysfunction\nEstimated
  primary completion: 1 February 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/cyclosporine-vevye#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07224529
URL:https://assetmemo.bio/drug/cyclosporine-vevye#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904728-5582@assetmemo.bio
DTSTAMP:20261121T010000Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Cyclosporine (Vevye): Phase na readout est. (NCT07904728)
DESCRIPTION:Cyclosporine (Vevye)\, phase na\, Dry Eye Disease.\nStudy: Trea
 ting Contact Lens Discomfort With Cyclosporine 0.1% Ophthalmic Solution\nE
 stimated primary completion: 15 March 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cyclosporine-vevye#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07904728
URL:https://assetmemo.bio/drug/cyclosporine-vevye#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368595-5582@assetmemo.bio
DTSTAMP:20261121T010000Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cyclosporine (Vevye): Phase 4 readout est. (NCT07368595)
DESCRIPTION:Cyclosporine (Vevye)\, phase 4\, Dry Eye Disease.\nStudy: Compa
 rison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With
  Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic
  0.05% Cyclosporine Emulsion for 8 Weeks\nEstimated primary completion: 31
  March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cyclospo
 rine-vevye#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07368595
URL:https://assetmemo.bio/drug/cyclosporine-vevye#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
